A股異動 | 巨星科技高開回落 現升6% 口罩產品備案申請獲美國批准
格隆匯3月17日丨巨星科技(002444.SZ)盤前競價強勢漲停,開盤後逐步回落。現漲幅收窄至5.92%,報11.1元,暫成交4.13億元,最新總市值119.35億元。巨星科技昨日公佈,近日,公司收到美國食品藥品監督管理局(“美國FDA”)的通知,公司向美國FDA申請的產品備案申請獲得批准。產品名稱:MASK,SCAVENGING(防護口罩,“防護口罩”)。公司將可以在美國市場全面銷售上述產品,並依據訂單情況配套相應產能,努力為公司帶來新的盈利增長點,確保公司業務穩定持續發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.